About Athersys (NASDAQ:ATHX)
Athersys, Inc. is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company's MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients. In the neurological area, the Company evaluated in a completed Phase II trial, the potential for MultiStem treatment of patients with a history of neurological damage from an ischemic stroke. The Company initiated a Phase II clinical study in the United States for the administration of MultiStem cell therapy to patients with a history of an acute myocardial infarction, or AMI.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ATHX
CUSIPN/A
Phone216-431-9900
Debt
Debt-to-Equity RatioN/A
Current Ratio3.09%
Quick Ratio3.09%
Price-To-Earnings
Trailing P/E Ratio-6.97
Forward P/E Ratio-5.94
P/E GrowthN/A
Sales & Book Value
Annual Sales$3.71 million
Price / Sales68.51
Cash FlowN/A
Price / CashN/A
Book Value$0.20 per share
Price / Book10.10
Profitability
EPS (Most Recent Fiscal Year)($0.29)
Net Income$-32,240,000.00
Net Margins-869.50%
Return on Equity-123.22%
Return on Assets-94.58%
Miscellaneous
Employees66
Outstanding Shares125,830,000
Athersys (NASDAQ:ATHX) Frequently Asked Questions
What is Athersys' stock symbol?
Athersys trades on the NASDAQ under the ticker symbol "ATHX."
How were Athersys' earnings last quarter?
Athersys (NASDAQ:ATHX) released its earnings results on Tuesday, March, 13th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.07) by $0.04. The biopharmaceutical company earned $1.17 million during the quarter, compared to analysts' expectations of $0.42 million. Athersys had a negative net margin of 869.50% and a negative return on equity of 123.22%. Athersys's revenue for the quarter was up 19.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.10) earnings per share. View Athersys' Earnings History.
When is Athersys' next earnings date?
What price target have analysts set for ATHX?
1 Wall Street analysts have issued 12-month price objectives for Athersys' stock. Their forecasts range from $6.00 to $6.00. On average, they expect Athersys' share price to reach $6.00 in the next year. View Analyst Ratings for Athersys.
What are Wall Street analysts saying about Athersys stock?
Here are some recent quotes from research analysts about Athersys stock:
- 1. According to Zacks Investment Research, "Athersys is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The company's lead product candidate, ATHX-105, is an oral, selective 5HT2c receptor agonist in Phase I clinical trials for the treatment of obesity. The company is also developing other orally active pharmaceutical product candidates for the treatment of metabolic and central nervous system disorders, utilizing proprietary technologies, including Random Activation of Gene Expression (RAGE). Athersys is developing MultiStem(r), its patented, adult-derived ``off the shelf'' stem cell product platform, for multiple disease indications, including damage caused by myocardial infarction, bone marrow transplantation/oncology support, ischemic stroke and other indications. " (4/18/2018)
- 2. Maxim Group analysts commented, "Summary Athersys issued a press release this morning ahead of their scheduled earnings release and conference call tonight. News is that the company will significantly expand their existing development and commercialization collaboration with partner Healios (6927JP – ¥998 – NR). Healios will make a ~$21M equity investment at $1.76 per share, a premium to Athersys current share price of $1.56. Specifics mentioned:." (3/13/2018)
Who are some of Athersys' key competitors?
Some companies that are related to Athersys include Achillion Pharmaceuticals (ACHN), ObsEva (OBSV), Zealand Pharma (ZEAL), MediciNova (MNOV), Innate Pharma (IPHYF), ProMetic Life Sciences (PFSCF), Isotechnika Pharma (AUPH), Sinovac Biotech (SVA), Concert Pharmaceuticals (CNCE), Synergy Pharmaceuticals (SGYP), Depomed (DEPO), Syros Pharmaceuticals (SYRS), Cara Therapeutics (CARA), Albireo Pharma (ALBO), Kala Pharmaceuticals (KALA), Corbus Pharmaceuticals (CRBP), Mersana Therapeutics (MRSN) and Cytokinetics (CYTK).
Who are Athersys' key executives?
Athersys' management team includes the folowing people:
- Gil Van Bokkelen Ph.D., Chairman of the Board, Chief Executive Officer (Age 56)
- William B.J. Lehmann Jr. J.D., President, Chief Operating Officer (Age 51)
- John J. Harrington Ph.D., Executive Vice President, Chief Scientific Officer, Director (Age 49)
- Laura K. Campbell CPA, Senior Vice President - Finance (Age 53)
- Lee E. Babiss Ph.D., Lead Independent Director (Age 61)
- Jordan S. Davis, Independent Director (Age 55)
- Ismail Kola, Independent Director (Age 60)
- Lorin Jeffry Randall, Independent Director (Age 73)
- Jack L. Wyszomierski, Independent Director (Age 61)
Has Athersys been receiving favorable news coverage?
Media coverage about ATHX stock has been trending somewhat positive on Saturday, Accern Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Athersys earned a media sentiment score of 0.16 on Accern's scale. They also assigned press coverage about the biopharmaceutical company an impact score of 45.83 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
How do I buy shares of Athersys?
Shares of ATHX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Athersys' stock price today?
One share of ATHX stock can currently be purchased for approximately $2.02.
How big of a company is Athersys?
Athersys has a market capitalization of $254.18 million and generates $3.71 million in revenue each year. The biopharmaceutical company earns $-32,240,000.00 in net income (profit) each year or ($0.29) on an earnings per share basis. Athersys employs 66 workers across the globe.
How can I contact Athersys?
Athersys' mailing address is 3201 CARNEGIE AVENUE, CLEVELAND OH, 44115. The biopharmaceutical company can be reached via phone at 216-431-9900 or via email at [email protected]
MarketBeat Community Rating for Athersys (ATHX)
MarketBeat's community ratings are surveys of what our community members think about Athersys and other stocks. Vote "Outperform" if you believe ATHX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATHX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Athersys (NASDAQ:ATHX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
1 Wall Street analysts have issued ratings and price targets for Athersys in the last 12 months. Their average twelve-month price target is $6.00, suggesting that the stock has a possible upside of 197.03%. The high price target for ATHX is $6.00 and the low price target for ATHX is $6.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $6.00 | $6.00 | $9.50 | $9.50 |
| Price Target Upside: | 197.03% upside | 284.62% upside | 433.71% upside | 288.55% upside |
Athersys (NASDAQ:ATHX) Consensus Price Target History
Athersys (NASDAQ:ATHX) Analyst Ratings History
Show:
(Data available from 4/21/2016 forward)
Athersys (NASDAQ:ATHX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Athersys (NASDAQ ATHX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 9.40%
Institutional Ownership Percentage: 19.29%
Athersys (NASDAQ ATHX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/20/2018 | William Lehmann Jr | Insider | Sell | 14,000 | $1.89 | $26,460.00 | 481,973 |  |
| 3/16/2018 | John J Harrington | EVP | Sell | 15,000 | $1.84 | $27,600.00 | | |
| 12/19/2017 | William Lehmann Jr | COO | Sell | 14,000 | $1.80 | $25,200.00 | 503,712 | |
| 12/18/2017 | John J Harrington | EVP | Sell | 7,500 | $1.77 | $13,275.00 | 658,474 | |
| 12/15/2017 | John J Harrington | EVP | Sell | 7,500 | $1.68 | $12,600.00 | 658,474 | |
| 9/19/2017 | William Lehmann Jr | Insider | Sell | 15,000 | $2.38 | $35,700.00 | 527,380 | |
| 9/18/2017 | John J Harrington | EVP | Sell | 15,000 | $2.17 | $32,550.00 | 679,416 | |
| 6/16/2017 | John J Harrington | EVP | Sell | 36,000 | $1.45 | $52,200.00 | 712,743 | |
| 2/1/2017 | Ismail Kola | Director | Buy | 15,000 | $1.01 | $15,150.00 | 15,000 | |
| 2/1/2017 | Laura K Campbell | Insider | Buy | 20,000 | $1.01 | $20,200.00 | 501,815 | |
| 12/19/2016 | William Lehmann Jr | Insider | Sell | 3,000 | $1.60 | $4,800.00 | 395,101 | |
| 12/16/2016 | John J Harrington | EVP | Sell | 15,000 | $1.60 | $24,000.00 | 599,392 | |
| 9/19/2016 | William Lehmann Jr | Insider | Sell | 3,000 | $1.96 | $5,880.00 | 403,459 | |
| 9/16/2016 | John J Harrington | EVP | Sell | 15,000 | $1.96 | $29,400.00 | 619,639 | |
| 6/21/2016 | William Lehmann Jr | COO | Sell | 25,000 | $2.17 | $54,250.00 | 279,017 | |
| 3/21/2016 | William Lehmann Jr | COO | Sell | 25,000 | $2.41 | $60,250.00 | 319,720 | |
| 12/21/2015 | William Lehmann, Jr. | COO | Sell | 25,000 | $1.03 | $25,750.00 | 335,346 | |
| 9/21/2015 | Bokkelen Gil Van | CEO | Sell | 9,500 | $1.36 | $12,920.00 | 901,665 | |
| 9/21/2015 | John J. Harrington | EVP | Sell | 8,150 | $1.36 | $11,084.00 | 531,056 | |
| 9/21/2015 | William Lehmann, Jr. | COO | Sell | 25,000 | $1.36 | $34,000.00 | 376,049 | |
| 6/22/2015 | William Lehmann Jr | COO | Sell | 25,000 | $1.21 | $30,250.00 | | |
| 6/19/2015 | John J Harrington | Insider | Sell | 8,150 | $1.23 | $10,024.50 | | |
| 6/19/2015 | Robert J Deans | EVP | Sell | 5,080 | $1.23 | $6,248.40 | | |
| 6/9/2015 | Kenneth H Traub | Director | Buy | 30,000 | $1.27 | $38,100.00 | | |
| 3/20/2015 | William Lehmann Jr | COO | Sell | 25,000 | $3.14 | $78,500.00 | | |
| 3/19/2015 | Bokkelen Gil Van | CEO | Sell | 9,500 | $3.10 | $29,450.00 | | |
| 3/19/2015 | Robert J Deans | EVP | Sell | 5,080 | $3.10 | $15,748.00 | | |
| 12/19/2014 | Bokkelen Gil Van | CEO | Sell | 9,500 | $1.29 | $12,255.00 | | |
| 12/19/2014 | Robert J Deans | EVP | Sell | 5,080 | $1.28 | $6,502.40 | | |
| 12/19/2014 | William Lehmann Jr | COO | Sell | 30,000 | $1.29 | $38,700.00 | | |
| 9/24/2014 | Kenneth H Traub | Director | Buy | 30,000 | $1.39 | $41,700.00 | | |
| 9/22/2014 | William Lehmann Jr | COO | Sell | 30,000 | $1.40 | $42,000.00 | | |
| 9/19/2014 | Bokkelen Gil Van | CEO | Sell | 9,500 | $1.41 | $13,395.00 | | |
| 9/19/2014 | John J Harrington | Insider | Sell | 8,150 | $1.41 | $11,491.50 | | |
| 9/19/2014 | Robert J Deans | EVP | Sell | 5,080 | $1.41 | $7,162.80 | | |
| 8/18/2014 | Lorin Randall | Director | Sell | 15,000 | $1.54 | $23,100.00 | | |
| 6/20/2014 | William Lehmann Jr | COO | Sell | 12,000 | $1.58 | $18,960.00 | | |
| 6/19/2014 | Bokkelen Gil Van | CEO | Sell | 9,500 | $1.63 | $15,485.00 | | |
| 6/19/2014 | John J Harrington | Insider | Sell | 8,150 | $1.63 | $13,284.50 | | |
| 6/19/2014 | Robert J Deans | EVP | Sell | 5,080 | $1.63 | $8,280.40 | | |
| 6/19/2014 | William Lehmann Jr | COO | Sell | 13,000 | $1.62 | $21,060.00 | | |
| 3/20/2014 | William Lehmann Jr | COO | Sell | 25,000 | $3.62 | $90,500.00 | | |
| 3/18/2014 | Bokkelen Gil Van | CEO | Sell | 9,500 | $3.54 | $33,630.00 | | |
| 3/18/2014 | John J Harrington | Insider | Sell | 8,150 | $3.54 | $28,851.00 | | |
| 3/18/2014 | Robert J Deans | EVP | Sell | 5,080 | $3.54 | $17,983.20 | | |
| 12/20/2013 | William Lehmann Jr | COO | Sell | 25,000 | $2.13 | $53,250.00 | | |
| 12/11/2013 | Kenneth H Traub | Director | Buy | 20,000 | $1.94 | $38,800.00 | | |
| 9/20/2013 | John J Harrington | Insider | Sell | 30,000 | $1.82 | $54,600.00 | | |
| 9/20/2013 | William Lehmann Jr | COO | Sell | 12,000 | $1.83 | $21,960.00 | | |
| 11/28/2012 | Laura K Campbell | VP | Buy | 10,000 | $1.01 | $10,100.00 | | |
| 11/15/2012 | Robert J Deans | EVP | Buy | 3,500 | $0.99 | $3,465.00 | | |
(Data available from 1/1/2013 forward)
Athersys (NASDAQ ATHX) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Athersys (ATHX) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - April 18 at 6:22 PM |
| Athersys (ATHX) Upgraded to "Buy" at Zacks Investment Research
www.americanbankingnews.com - April 17 at 6:28 PM |
 | Athersys/Healios Warrant Structure Bullish For Athersys Shares
seekingalpha.com - April 16 at 5:25 PM |
 | Athersys to Host First Quarter Financial Results Call
finance.yahoo.com - April 12 at 5:39 PM |
| Edited Transcript of ATHX conference call or presentation 28-Jul-10 8:30pm GMT
finance.yahoo.com - April 12 at 5:39 PM |
| ValuEngine Downgrades Athersys (ATHX) to Sell
www.americanbankingnews.com - April 8 at 1:29 PM |
| Wired News – Reata Pharma Reports Positive Top-line Data from its Phase-2 LARIAT Trial
finance.yahoo.com - March 26 at 8:22 AM |
| Athersys (ATHX) Upgraded to Hold at ValuEngine
www.americanbankingnews.com - March 23 at 11:22 PM |
| Analyzing Athersys (ATHX) and ARMO BioSciences (ARMO)
www.americanbankingnews.com - March 23 at 3:26 AM |
| Insider Selling: Athersys, Inc. (ATHX) Insider Sells 14,000 Shares of Stock
www.americanbankingnews.com - March 21 at 1:26 PM |
 | Athersys to Present at Needham Healthcare Conference on March 28
feeds.benzinga.com - March 20 at 2:31 PM |
| Athersys, Inc. (ATHX) EVP John J. Harrington Sells 15,000 Shares
www.americanbankingnews.com - March 19 at 8:30 PM |
| Athersys' (ATHX) Buy Rating Reiterated at Maxim Group
www.americanbankingnews.com - March 18 at 10:24 AM |
| Edited Transcript of ATHX earnings conference call or presentation 13-Mar-18 8:30pm GMT
finance.yahoo.com - March 18 at 8:17 AM |
| Brokers Issue Forecasts for Athersys, Inc.'s Q1 2018 Earnings (ATHX)
www.americanbankingnews.com - March 16 at 8:50 AM |
| Brokers Set Expectations for Athersys, Inc.'s Q1 2019 Earnings (ATHX)
www.americanbankingnews.com - March 15 at 11:44 AM |
| Athersys (ATHX) Announces Earnings Results, Misses Estimates By $0.04 EPS
www.americanbankingnews.com - March 14 at 8:44 AM |
| A Bombshell Day For Athersys: Earnings, Partnership, And New Indications - Seeking Alpha
seekingalpha.com - March 14 at 8:32 AM |
 | Athersys, Inc.: Athersys and Healios Announce Binding Letter of Intent to Expand MultiStem Collaboration
www.finanznachrichten.de - March 13 at 7:17 PM |
| Athersys Reports Financial Results for Fourth Quarter, Full Year 2017
finance.yahoo.com - March 13 at 7:17 PM |
 | Athersys and HEALIOS Announce Binding Letter of Intent to Expand MultiStem® Collaboration - GlobeNewswire (press release)
globenewswire.com - March 13 at 8:25 AM |
| Athersys and Healios Announce Binding Letter of Intent to Expand ... - GlobeNewswire (press release)
globenewswire.com - March 13 at 8:25 AM |
| Athersys and HEALIOS Announce Binding Letter of Intent to Expand MultiStem® Collaboration
finance.yahoo.com - March 13 at 8:25 AM |
| Athersys (ATHX) Downgraded by ValuEngine
www.americanbankingnews.com - March 4 at 11:42 PM |
| Athersys (ATHX) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - February 28 at 1:24 AM |
| Athersys: Is It Worth Your Time? - Seeking Alpha
seekingalpha.com - February 21 at 8:21 AM |
| Selling Into A Void - Athersys Moves In Ignorance - Seeking Alpha
seekingalpha.com - February 16 at 8:17 AM |
| Athersys (ATHX) Given a $6.00 Price Target at Maxim Group
www.americanbankingnews.com - February 13 at 5:24 PM |
| Athersys Enters Into New $100 Million Equity Facility with Aspire Capital - GlobeNewswire (press release)
globenewswire.com - February 4 at 9:25 AM |
| Athersys Enters Into New $100 Million Equity Facility with Aspire Capital
feeds.benzinga.com - February 2 at 7:45 AM |
 | This Morning's Technical Outlook on Biotech Stocks -- Aptose Biosciences, Athersys, AVEO Pharma, and Aviragen Therapeutics
www.bizjournals.com - February 1 at 9:39 AM |
| Athersys CEO to Speak at the 2018 Brain Health Summit
feeds.benzinga.com - January 29 at 6:52 AM |
| Athersys (ATHX) & ZS Pharma (ZSPH) Critical Analysis
www.americanbankingnews.com - January 22 at 7:24 PM |
| Athersys, Inc. (ATHX) EVP John J. Harrington Sells 7,500 Shares
www.americanbankingnews.com - December 19 at 6:52 PM |
| Athersys, Inc. (ATHX) COO William Lehmann, Jr. Sells 14,000 Shares
www.americanbankingnews.com - December 19 at 6:26 PM |
| Athersys (ATHX) Downgraded by ValuEngine to "Sell"
www.americanbankingnews.com - December 5 at 10:50 PM |
| Athersys, Inc. (ATHX) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - November 23 at 12:46 AM |
| Maxim Group Analysts Give Athersys, Inc. (ATHX) a $12.00 Price Target
www.americanbankingnews.com - November 16 at 10:18 PM |
| HEALIOS Announces Enrollment of First Patient in Japan in TREASURE Study of MultiStem® Treatment for Ischemic Stroke
finance.yahoo.com - November 16 at 11:35 AM |
| Brokerages Set $12.00 Price Target for Athersys, Inc. (ATHX)
www.americanbankingnews.com - November 13 at 7:30 PM |
 | Stocks Under Scanner in the Biotech Space -- Sangamo Therapeutics, Vertex Pharma, Athersys, and AVEO Pharma - PR Newswire (press release)
www.prnewswire.com - November 10 at 1:41 PM |
| Edited Transcript of ATHX earnings conference call or presentation 8-Nov-17 9:30pm GMT
finance.yahoo.com - November 9 at 5:19 PM |
| Athersys Reports Third Quarter 2017 Results - GlobeNewswire (press release)
globenewswire.com - November 9 at 4:29 AM |
| Athersys, Inc. to Host Earnings Call
finance.yahoo.com - November 8 at 6:24 PM |
| Athersys Reports Third Quarter 2017 Results
finance.yahoo.com - November 8 at 6:24 PM |
| Athersys, Inc. (ATHX) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - October 31 at 9:58 AM |
| Bears On Parade - Regardless, Athersys Is Developing Key Relationships For A Successful Future
seekingalpha.com - October 14 at 2:43 AM |
| Featured Company News - Athersys Signs Agreement with Nikon CeLL Innovation for Commercial Manufacturing of MultiStem in Japan
finance.yahoo.com - October 13 at 4:39 PM |
| Athersys Partners Up: Can Nikon CeLL Get MultiStem On Track? - Seeking Alpha
seekingalpha.com - October 13 at 2:58 AM |
 | Athersys (ATHX) in Focus: Stock Moves 7.2% Higher - Nasdaq
www.nasdaq.com - October 13 at 2:58 AM |
Athersys (NASDAQ:ATHX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Athersys (NASDAQ:ATHX) Income Statement, Balance Sheet and Cash Flow Statement
Athersys (NASDAQ ATHX) Stock Chart for Saturday, April, 21, 2018
Loading chart…
